'Transformative' Dupilumab Set For Third Quarter Filing In Atopic Dermatitis
This article was originally published in Scrip
Executive Summary
Sanofi and Regeneron Pharmaceuticals Inc. are on schedule to file for approval of dupilumab for the treatment of atopic dermatitis in the third quarter of this year following positive data from two Phase III studies, SOLO 1 and SOLO 2.
You may also be interested in...
Sanofi/Regeneron Choose Access Over Price With Dupixent Launch
The FDA approved the IL-4/IL-13 inhibitor March 28 in a win for Sanofi and Regeneron. The companies set the biologic's price at $37,000 per year, which is lower than many biologics on the market for psoriasis.
10 Approvals To Watch For In Early 2017
Dupixent, Austedo, brigatinib and Olumiant are among a raft of new drug approvals expected in the first four months of the year. Here, with help from Informa Pharma's Biomedtracker, we take a look at 10 of the more interesting products looking close to reaching the market, some for the second time of asking.
Keeping Track: Submissions For Dupilumab, Nusinersen; AbbVie Finds Breakthrough Space In Hep C
The latest drug development news and highlights from our FDA Performance Tracker.